LGVN

+ Watchlist + Portfolio

Longeveron Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.59
52-Week Range: $2.30 – $12.30
Market Cap: $8.23M
P/E (TTM): —
EPS (TTM): -9.90
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.79
PEG Ratio: —
Return on Equity: -203.61%
Return on Assets: -90.95%
Gross Margin: 69.76%
Operating Margin: -2150.17%
Profit Margin: 0.00%
Current Ratio: 2.63
Debt/Equity: 0.06
Total Debt: $581.00K
Free Cash Flow: $-11.60M
Revenue Growth: -9.20%
Earnings Growth: —
Enterprise Value: $-1.27M

LGVN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.22M	$709.00K	$2.39M	$1.20M
Cost of Revenue	$725.00K	$488.00K	$508.00K	$396.00K
Gross Profit	$497.00K	$221.00K	$1.88M	$803.00K
Research & Development	$9.37M	$9.07M	$8.14M	$12.04M
Selling, General & Admin	$9.17M	$12.18M	$10.27M	$12.05M
Operating Expenses	$18.54M	$21.25M	$18.41M	$24.09M
Operating Income	-$18.04M	-$21.03M	-$16.52M	-$23.29M
EBITDA	-$17.15M	-$20.08M	-$15.56M	-$22.06M
Pretax Income	-$18.84M	-$21.41M	-$15.97M	-$22.70M
Net Income	-$18.84M	-$21.41M	-$15.97M	-$22.70M
Diluted EPS	-9.00	-10.22	-2.62	-1.29
Diluted Shares	2.10M	2.17M	9.41M	17.58M

LGVN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$10.50M	$4.95M	$19.23M	$4.66M
Receivables	$218.00K	$111.00K	$84.00K	$104.00K
Current Assets	$20.28M	$5.85M	$19.62M	$5.45M
Total Assets	$27.41M	$12.08M	$25.56M	$10.26M
Current Liabilities	$4.87M	$3.89M	$2.58M	$4.09M
Total Debt	$2.60M	$2.04M	$1.45M	$824.00K
Total Liabilities	$6.91M	$5.34M	$3.67M	$4.59M
Retained Earnings	-$62.77M	-$84.98M	-$109.61M	-$132.31M
Shareholders' Equity	$20.50M	$6.74M	$21.89M	$5.67M
Working Capital	$15.41M	$1.96M	$17.04M	$1.36M

LGVN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.97M	-$19.00M	-$13.87M	-$18.64M
Capital Expenditure	-$856.00K	-$694.00K	-$992.00K	-$595.00K
Free Cash Flow	-$14.82M	-$19.70M	-$14.86M	-$19.24M
Depreciation & Amortisation	$893.00K	$946.00K	$958.00K	$1.23M
Stock-Based Compensation	$2.17M	$2.03M	$2.33M	$1.68M
Investing Cash Flow	-$677.00K	$8.19M	-$640.00K	-$595.00K
Financing Cash Flow	-$509.00K	$5.26M	$28.79M	$4.67M
Net Change in Cash	-$15.15M	-$5.55M	$14.28M	-$14.57M

LGVN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$381.00K	$316.00K	$137.00K	$365.00K	$398.00K	$287.00K
Cost of Revenue	$106.00K	$170.00K	$12.00K	$108.00K	$134.00K	$105.00K
Gross Profit	$275.00K	$146.00K	$125.00K	$257.00K	$264.00K	$182.00K
Research & Development	$2.52M	$2.95M	$3.85M	$2.72M	$2.32M	$3.19M
Selling, General & Admin	$2.94M	$2.59M	$3.58M	$2.94M	$2.72M	$3.16M
Operating Expenses	$5.46M	$5.54M	$7.43M	$5.66M	$5.04M	$6.35M
Operating Income	-$5.18M	-$5.40M	-$7.31M	-$5.40M	-$4.78M	-$6.17M
EBITDA	-$4.76M	-$5.13M	-$7.05M	-$5.12M	-$4.52M	-$5.95M
Pretax Income	-$5.01M	-$5.03M	-$7.22M	-$5.44M	-$4.74M	-$6.07M
Net Income	-$5.01M	-$5.03M	-$7.22M	-$5.44M	-$4.74M	-$6.07M
Diluted EPS	-0.34	-0.33	-0.39	—	-0.19	-0.19
Diluted Shares	14.95M	15.01M	18.37M	—	24.79M	31.38M

LGVN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$14.33M	$10.33M	$9.24M	$4.66M	$15.76M	$10.08M
Receivables	$29.00K	$31.00K	$52.00K	$104.00K	$68.00K	$65.00K
Current Assets	$15.28M	$11.27M	$10.34M	$5.45M	$16.86M	$11.32M
Total Assets	$20.85M	$16.75M	$15.56M	$10.26M	$21.21M	$15.49M
Current Liabilities	$2.72M	$3.28M	$4.94M	$4.09M	$4.34M	$4.31M
Total Debt	$1.29M	$1.14M	$983.00K	$824.00K	$748.00K	$581.00K
Total Liabilities	$3.69M	$4.09M	$5.59M	$4.59M	$5.18M	$5.08M
Retained Earnings	-$114.62M	-$119.65M	-$126.87M	-$132.31M	-$137.05M	-$143.12M
Shareholders' Equity	$17.16M	$12.66M	$9.97M	$5.67M	$16.03M	$10.40M
Working Capital	$12.55M	$7.99M	$5.40M	$1.36M	$12.51M	$7.02M

LGVN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$4.70M	-$3.60M	-$5.05M	-$5.30M	-$4.37M	-$5.65M
Capital Expenditure	-$150.00K	-$263.00K	-$118.00K	-$64.00K	-$20.00K	-$103.00K
Free Cash Flow	-$4.85M	-$3.86M	-$5.17M	-$5.36M	-$4.39M	-$5.76M
Depreciation & Amortisation	$421.00K	$263.00K	$264.00K	$278.00K	$252.00K	$221.00K
Stock-Based Compensation	$340.00K	$513.00K	$448.00K	$376.00K	$379.00K	$373.00K
Investing Cash Flow	-$150.00K	-$263.00K	-$118.00K	-$64.00K	-$20.00K	-$103.00K
Financing Cash Flow	-$58.00K	-$133.00K	$4.08M	$777.00K	$15.49M	$75.00K
Net Change in Cash	-$4.91M	-$3.99M	-$1.09M	-$4.58M	$11.10M	-$5.68M

Market Snapshot

About

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies based on Medicinal Signaling Cells (MSCs). The company's lead product candidate targets aging-related and life-threatening conditions including Alzheimer's disease, aging frailty, and acute respiratory distress syndrome. Longeveron's research focuses on harnessing the body's natural healing mechanisms to address diseases with significant unmet medical needs.